Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Sci Rep. 2013;3:2498. doi: 10.1038/srep02498.
Cell-based therapies using pluripotent stem cells hold great promise as regenerative approaches to treat many types of diseases. Nevertheless many challenges remain and, perhaps foremost, is the issue of how to direct and enhance the specification and differentiation of a desired cell type for potential therapeutics. We have examined the molecular basis for the inverse correlation of cardiac and skeletal myogenesis in small molecule-enhanced stem cell differentiation. Our study shows that activation of premyogenic factor Pax3 coincides with inhibiting gene expression of early cardiac factor GATA4. Interestingly, the inhibitory effect of small molecules on cardiac differentiation depends on the function of Pax3, but not the mesoderm factor Meox1. Thus Pax3 is an inhibitor of cardiac differentiation in lineage specification. Our studies reveal the dual roles of Pax3 in stem cell fate determinations and provide new molecular insights into small molecule-enhanced lineage specification.
基于多能干细胞的细胞疗法作为一种再生方法,有望治疗多种类型的疾病。然而,仍然存在许多挑战,也许首先是如何指导和增强所需细胞类型的特化和分化,以实现潜在的治疗效果。我们研究了小分子增强的干细胞分化中心脏和骨骼肌发生的反比相关性的分子基础。我们的研究表明,前肌生成因子 Pax3 的激活与抑制早期心脏因子 GATA4 的基因表达同时发生。有趣的是,小分子对心脏分化的抑制作用取决于 Pax3 的功能,而不依赖于中胚层因子 Meox1。因此,Pax3 是谱系特化中心脏分化的抑制剂。我们的研究揭示了 Pax3 在干细胞命运决定中的双重作用,并为小分子增强谱系特化提供了新的分子见解。